Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Meir Schechter, Stephen D. Wiviott, Itamar Raz, Erica L. Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Martin Fredriksson, Peter A. Johansson, Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S. Sabatine, Ofri Mosenzon
Topics & Concepts
MedicineDapagliflozinType 2 diabetesDiabetes mellitusPost-hoc analysisInternal medicineTIMIPlaceboPopulationHazard ratioDiseaseEndocrinologyMyocardial infarctionConfidence intervalPathologyEnvironmental healthThrombolysisAlternative medicineDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsPancreatic function and diabetes